Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cario

Showing results (501-510 of 548) with videos related to

Pageof 55
Sort By:
Hemasphere|September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapyGunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2017
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndromeOmer Schwartzman, Angela Maria Savino, Michael Gombert, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Haematologica|January 26, 2023
Comprehensive <i>in silico</i> and functional studies for classification of <i>EPAS1/HIF2A</i> genetic variants identified in patients with erythrocytosisValéna Karaghiannis, Darko Maric, Céline Garrec, et al.
The Lancet. Haematology|December 28, 2020
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort studyMonique L den Boer, Gunnar Cario, Anthony V Moorman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Plos Pathogens|April 1, 2020
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyPaul David, Malgorzata Drabczyk-Pluta, Eva Pastille, et al.
Clinical Chemistry and Laboratory Medicine|February 10, 2021
High-resolution pediatric reference intervals for 15 biochemical analytes described using fractional polynomialsJakob Zierk, Hannsjörg Baum, Alexander Bertram, et al.
Pageof 55

Showing results (501-510 of 548) with videos related to

Sort By:
Pageof 55
Hemasphere|September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapyGunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2017
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndromeOmer Schwartzman, Angela Maria Savino, Michael Gombert, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Haematologica|January 26, 2023
Comprehensive <i>in silico</i> and functional studies for classification of <i>EPAS1/HIF2A</i> genetic variants identified in patients with erythrocytosisValéna Karaghiannis, Darko Maric, Céline Garrec, et al.
The Lancet. Haematology|December 28, 2020
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort studyMonique L den Boer, Gunnar Cario, Anthony V Moorman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Plos Pathogens|April 1, 2020
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyPaul David, Malgorzata Drabczyk-Pluta, Eva Pastille, et al.
Clinical Chemistry and Laboratory Medicine|February 10, 2021
High-resolution pediatric reference intervals for 15 biochemical analytes described using fractional polynomialsJakob Zierk, Hannsjörg Baum, Alexander Bertram, et al.
Pageof 55